

October 25, 2024

Data Privacy & Security for the Life Sciences

Trinity Car
Syneos Health

Joanne Charles
Gilead Sciences

Andrew Epstein
Cooley LLP

Nicole Shoemaker
Tourmaline Bio

Speakers



Andrew Epstein

Special Counsel
Cooley LLP
aepstein@cooley.com




Trinity Car

Managing Counsel
Syneos Health
Trinity.car@syneoshealth.com



Joanne Charles

Associate General Counsel
Gilead Sciences
Joanne.Charles@gilead.com



Nicole Shoemaker

Associate General Counsel
Tourmaline Bio
nshoemaker@tourmalinebio.com

Agenda

- Initial considerations for clinical trial activities
- Maintaining the data
- Exit considerations and leveraging the data
- Key takeaways
- Questions

Questions & Contacts



Andrew Epstein

Special Counsel
Cooley LLP
aepstein@cooley.com




Trinity Car

Managing Counsel
Syneos Health
Trinity.car@syneoshealth.com



Joanne Charles

Associate General Counsel
Gilead Sciences
Joanne.Charles@gilead.com



Nicole Shoemaker

Associate General Counsel
Tourmaline Bio
nshoemaker@tourmalinebio.com